PUBLISHER: Lucintel | PRODUCT CODE: 1386130
PUBLISHER: Lucintel | PRODUCT CODE: 1386130
The future of the global typhoid fever vaccine market looks promising with opportunities in the hospital & clinic and specialty center markets. The global typhoid fever vaccine market is expected to reach an estimated $1.0 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are rise in the prevalence of typhoid and growing demand for combined vaccines that offer protection against multiple diseases.
A more than 150-page report is developed to help in your business decisions.
The study includes a forecast for the global typhoid fever vaccine by type, route of administration, end use, and region.
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies typhoid fever vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the typhoid fever vaccine companies profiled in this report include-
Lucintel forecasts that capsular polysaccharide is expected to witness highest growth over the forecast period due to its efficiency at preventing infection from the bacteria, safe with limited side effects, and it can be administered orally or by injection, making them easy and convenient to use.
Within this market, hospital & clinic is expected to witness highest growth over the forecast period.
North America will remain the largest region due to increasing demand for vaccines across all age groups and high awareness for the typhoid vaccines in the region.
Market Size Estimates: Typhoid fever vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Typhoid fever vaccine market size by type, route of administration, end use, and region in terms of value ($B).
Regional Analysis: Typhoid fever vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, route of administration, end uses, and regions for the typhoid fever vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the typhoid fever vaccine market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Answer: The global typhoid fever vaccine market is expected to reach an estimated $1.0 billion by 2030.
Answer: The global typhoid fever vaccine market is expected to grow with a CAGR of 14.5% from 2024 to 2030.
Answer: The major drivers for this market are rise in the prevalence of typhoid and growing demand for combined vaccines that offer protection against multiple diseases.
Answer: The future of the typhoid fever vaccine market looks promising with opportunities in the hospital & clinic and specialty center markets.
Answer: Some of the key typhoid fever vaccine companies are as follows:
Answer: Lucintel forecasts that capsular polysaccharide is expected to witness highest growth over the forecast period due to its efficiency at preventing infection from the bacteria, safe with limited side effects, and it can be administered orally or by injection, making them easy and convenient to use.
Answer: North America will remain the largest region due to increasing demand for vaccines across all age groups and high awareness for the typhoid vaccines in the region.
Answer: Yes, Lucintel provides 10% customization without any additional cost.